Aligos Announces Phase 2a Topline Results of MASH Treatment ALG-055009

Aligos Therapeutics, Inc., a biopharmaceutical company specializing in liver and viral disease treatments, will announce topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist for treating metabolic-dysfunction associated steatohepatitis (MASH). The announcement is scheduled for Thursday, September 19, 2024, before the market opens.

Following the announcement, Aligos will host a conference call and webcast at 8:30 am ET/5:30 am PT, featuring a slide presentation. Participants can join via the Aligos website, where a replay will be available for 90 days post-event.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing best-in-class treatments for liver and viral diseases, including MASH, hepatitis B, and coronaviruses. With its strong R&D expertise, Aligos aims to address high unmet medical needs in these areas.